Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077

Clin Infect Dis. 2020 Jan 2;70(2):319-322. doi: 10.1093/cid/ciz439.


Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.

Keywords: CAB; HIV uninfected; cabotegravir; weight gain.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • HIV
  • HIV Infections* / drug therapy
  • Humans
  • Pyridones*
  • Weight Gain*


  • Anti-HIV Agents
  • Pyridones
  • cabotegravir